• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

    6/9/25 9:00:00 AM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNPX alert in real time by email

    Singular focus on Bittensor (TAO), the leading AI token by

    adoption and market capitalization

    James Altucher to lead TAO token strategy initiatives

    Planned initial acquisition of $10 million in TAO equates to over two times the Company's 

    current market capitalization; total acquisition target of $100 million

    NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.

    Synaptogenix plans to acquire $10 million in TAO tokens initially, which amounts to over two times the Company's current market valuation. The Company's strategy is targeted to acquire $100 million of TAO tokens. The initial acquisition will be funded by the Company's significant cash reserves and well-capitalized balance sheet.

    Joshua Silverman, Chairman of the Board, stated, "Near the end of 2024, our Board of Directors began exploring value creation opportunities to best utilize our significant cash reserves. We have witnessed an increasing number of public and private companies allocate digital assets to their corporate treasuries successfully or use them as part of their business strategies. We believe the leading AI token, TAO, offers the best outlook for growth and adoption as well as the best opportunity to create and preserve value for our stockholders. We are fortunate to bring on James Altucher, a world-class authority on both AI and crypto, to drive revenue generation and TAO staking strategies in pursuit of significantly increasing shareholder value."

    "Based on our initial review, we believe the fixed market supply of 21 million TAO tokens alongside rapidly increasing global demand for AI development and adaptation makes TAO a compelling cryptocurrency," Silverman concluded.

    Mr. Altucher is an accomplished entrepreneur, venture capitalist, writer and author with decades of expertise in emerging technologies including crypto and AI. As an early proponent of Bitcoin, he created the first "Bitcoin-only" store. He has also published numerous academic papers on AI and delivered keynotes at prestigious AI conferences.

    "The AI industry is expected to grow tenfold between now and 2030, and some percentage of every dollar allocated to AI is expected to go towards decentralized AI where TAO is the clear leader. I am excited to be a part of what I believe is the only pure play public company focused on the convergence between crypto and AI as both industries continue to grow exponentially," said Altucher.

    TAO is the native token created for Bittensor, a decentralized blockchain network for machine learning and AI. Bittensor's open access and ownership environment for creating, training, and evaluating AI models is designed to democratize AI development. The network incentivizes participants, including miners and validators, based on the value of their contributions, as measured by information theory—such as the novelty, relevance, or efficiency of shared AI knowledge. Rewards are distributed in the form of TAO tokens.

    Synaptogenix intends to change its name and ticker symbol in accordance with its digital asset treasury strategy based on the AI token TAO. A new corporate website is also under development. More information will be available within the next several months.

    Synaptogenix announced that it has entered into securities purchase agreements for a $5.5 million financing, including James Altucher, involving the sale of 5,500 shares of its newly issued Series D convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a private placement and five year common stock purchase warrants, which is expected to close on or about June 10, 2025 subject to the satisfaction of customary closing conditions.

    The shares of Series D preferred stock have a conversion price of $3.00 per share. The warrants have an exercise price of $3.00 per common share. 

    The financing, consulting agreement with Mr. Altucher and certain management changes are more fully disclosed in the current report on Form 8-K filed with the SEC this morning.

    Forward-Looking Statements

    Any statements contained in this press release by Synaptogenix that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

    Contact

    800-811-5591

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-focused-exclusively-on-top-valued-ai-token-302476176.html

    SOURCE Synaptogenix, Inc.

    Get the next $SNPX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:07:09 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:45 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)

      4 - TAO Synergies Inc. (0001571934) (Issuer)

      7/2/25 4:06:21 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Synaptogenix Inc.

      PRE 14A - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:02:10 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TAO Synergies Inc. (0001571934) (Filer)

      6/27/25 4:00:50 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Synaptogenix, Inc. (0001571934) (Filer)

      6/24/25 4:37:19 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/6/24 10:16:19 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/8/23 6:05:21 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      1/18/23 4:28:57 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Financials

    Live finance-specific insights

    See more
    • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

      Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

      7/26/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Corporate Update Conference Call

      NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

      7/21/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

      NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

      7/26/21 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

      Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

      4/9/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

      New name and stock symbol highlight strategic commitment to TAO, the leading AI cryptocurrency NEW YORK, July 1, 2025 /PRNewswire/ -- TAO Synergies Inc. (NASDAQ:TAOX) (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), announces that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TAOX," effective at the market open today, July 1, 2025. The new name and trading symbol coincides with the Company's previously announced digital asset treasury strategy focused exclusively on acquiring and staking TAO cryptocurrency. Executive Chairman Joshua Silverman commented, "With our team's deep knowledge of the TAO ecosystem and relationships in

      7/1/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

      New trading symbol "TAOX" effective Tuesday, July 1, 2025, New name represents Company's strategic focus on the synergies between cryptocurrency and AI NEW YORK, June 26, 2025 /PRNewswire/ -- TAO Synergies Inc. (the "Company"), formerly Synaptogenix, Inc. (NASDAQ:SNPX), today announced that it will begin trading on Nasdaq under the new ticker symbol "TAOX" on Tuesday, July 1, 2025, in accordance with its rebranding to the new name TAO Synergies Inc., effective today. The Company's new corporate identity aligns with its significant  strategic focus on the leading AI token TAO as the cornerstone of its digital asset treasury strategy. TAO is the leading AI token by market capitalization and

      6/26/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

      Strategic capital deployment into TAO advances Synaptogenix's blockchain treasury model, leveraging BitGo's custody, trading and staking capabilities to generate token-based yield NEW YORK, June 24, 2025 /PRNewswire/ -- Synaptogenix (NASDAQ:SNPX) today announced its initial purchase of TAO as part of the Company's recently announced cryptocurrency treasury strategy focused exclusively on artificial intelligence (Al) and machine learning. BitGo, the leading infrastructure provider of digital asset solutions, has been selected to provide qualified custody, staking and trading services for Synaptogenix's TAO holdings. BitGo brings unmatched expertise and a proven track record to help Synaptogen

      6/24/25 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care